Thierry Passeron

USPTO Granted Patents = 7 (Patent Applications = 8)

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Batiment, FR (2015)
Nice, FR (2012 - 2024)

Company Filing History:

4 out of 1,745

Institut National De La Sante Et De La Recherche Medicale

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4. 3 out of 20

Université Cote D'azur

patents

5. 1 out of 1

University De Nice Sophia Antipolis

patent

6. 1 out of 5,094

Centre National De La Recherche Scientifique

patents

where one patent can have more than one assignee

Years Active: 2012-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048693 - Substituted halo-quinoline derivatives, method of preparation and applications thereof (2024-07-30),

2. 11650214 - Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders (2023-05-16),

3. 10983134 - Proteins of the WNT signaling pathway and uses thereof in the diagnostic and treatment of hypopigmentation disorders (2021-04-20),

4. 10632117 - GSK3B and uses thereof in the diagnostic and treatment of hypopigmentation disorders (2020-04-28),

5. 8946291 - Compositions and methods for treating pigmentary conditions and melanoma (2015-02-03),

6. 8476236 - Treatment of skin conditions by Dickkopf1 (DKK1) (2013-07-02),

7. 8198244 - Regulation of skin characteristics by DICKKOPF1 (DKK1) (2012-06-12),

Title: Thierry Passeron: Innovator in Pharmaceutical Chemistry

Introduction

Thierry Passeron is a notable inventor based in Nice, France, recognized for his contributions to pharmaceutical chemistry. With a total of seven patents to his name, he has made significant advancements in the treatment of various medical conditions, particularly in cancer and pigmentation disorders.

Latest Patents

One of Passeron's latest patents is focused on substituted halo-quinoline derivatives, which are compounds that have potential applications in cancer treatment. The invention details a compound of general formula (I), where specific substitutions are made to enhance its efficacy against solid tumor cancers, including melanoma, colon, lung, pancreas, kidney, and others. Additionally, he has developed a pharmaceutical composition that incorporates these compounds for therapeutic use.

Another significant patent involves the identification of proteins in the WNT signaling pathway as therapeutic targets for pigmentation disorders. This invention provides methods and products for diagnosing and treating hypopigmentation disorders, making it particularly relevant for human subjects. The innovative approach highlights the potential for these proteins to serve as biomarkers for pigmentation status.

Career Highlights

Throughout his career, Thierry Passeron has worked with esteemed institutions such as the National Institute of Health and Medical Research (Institut National De La Santé Et De La Recherche Médicale) and the University Hospital of Nice (Chu De Nice). His work in these organizations has contributed to his reputation as a leading figure in his field.

Collaborations

Passeron has collaborated with notable colleagues, including Florence Joly and Vincent J Hearing, further enhancing the impact of his research and innovations in pharmaceutical chemistry.

Conclusion

Thierry Passeron's work exemplifies the intersection of innovation and medical science, particularly in the development of treatments for cancer and pigmentation disorders. His patents reflect a commitment to advancing healthcare through research and invention.

This text is generated by artificial intelligence and may not be accurate.